Objective: Serum levels of microRNA have been proposed as biomarkers in various inflammatory diseases. However, up to now, their clinical relevance in critical illness and sepsis is unclear. Design: Single-center clinical study. Setting: Fourteen-bed medical ICU of the University Hospital Aachen, university laboratory research unit. Subjects and Patients: Experimental sepsis model in C57Bl/6 mice; 223 critically ill patients in comparison with 76 healthy volunteers.
use in diagnosis and follow-up of different human diseases (5) . However, at present, little is known about miRNAs deregulated in serum of patients with critical illness and sepsis.
Although previous studies in search of miRNA-based biomarkers for sepsis predominantly applied wide screening approaches in small cohorts (6) (7) (8) , we hypothesized that miR-NAs that are known to be functionally important in manifold inflammatory processes might represent interesting biomarkers in human sepsis. As such, a functional role of miR-29b (9, 10) , miR-125b (11, 12) , miR-133a (13, 14) , miR-150 (15, 16) , miR-155 (12, 17) , and miR-193b* (9, 18) was recently unraveled in systemic inflammatory responses associated with infections, fibrosis, heart infarction, autoimmune diseases, and cancer. Furthermore, most of these miRNAs are known down-stream targets of proinflammatory cytokines, such as bacterial lipopolysaccharides, tumor necrosis factor (TNF), and transforming growth factor-β (summarized in [19, 20] ), thus suggesting a deep integration of these miRNAs in proinflammatory signaling cascades driving inflammation and infection in general.
Based on this hypothesis, we first analyzed serum levels of these miRNAs in experimental polymicrobial sepsis in mice after cecal ligation and puncture, leading to the identification of a specific, 16-fold up-regulation of miR-133a. By translating these findings into a large, well-characterized cohort of 223 critically ill patients, serum levels of miR-133a in fact were elevated in patients with sepsis, associated with disease severity and indicated unfavorable short-and long-term prognosis.
MATERIALS AND METHODS

Study Design and Patient Characteristics
Two hundred twenty-three patients (140 men, 83 women, with a median age of 63 yr; range, 18-89 yr) who were consecutively admitted to the General Internal Medicine ICU at the University Hospital Aachen ( Table 1) were enrolled in this study. Only patients who were expected to have a long-term (> 72 hr) intensive care treatment were included into this study, meaning that patients who were admitted to the ICU due to postinterventional observation or acute intoxication were excluded from this study (21, 22) . Patients were treated in accordance to current guidelines for treatment of sepsis (Surviving Sepsis Campaign) (23) and specific guidelines of the respective boards. After release from the ICU, patients were observed in a further follow-up period of 3 years by directly contacting the patients, the patients' relatives, or their primary care physician. As a control population, we analyzed 76 healthy blood donors with normal values for blood counts, C-reactive protein (CRP), and liver enzymes. Based on recent functional data from experimental mouse models that indicated a role for the miRNAs miR-29b, miR-125b, miR-133a, miR-150, miR-155, and miR-193b* in critical illness (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , we analyzed serum levels of miR-133a both at the time point of patient's admission to the ICU and after 3 days of ICU treatment.
The study protocol was approved by the local ethics committee and conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (Ethics Committee of the University Hospital Aachen, RWTH-University, Aachen, Germany, reference number EK 150/06).
For further information please, see Supplementary Materials and Methods section (Supplemental Digital Content 1, http://links.lww.com/CCM/A805).
RESULTS
miR-133a Serum Levels Are Strongly and Specifically Up-Regulated in a Murine Model of Polymicrobial Sepsis
Functional data from experimental mouse models have indicated that the miRNAs miR-29b, miR-125b, miR-133a, miR-150, miR-155, and miR-193b* are critical regulators of inflammatory processes (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In order to test the potential value of these miRNAs as circulating biomarkers in sepsis, cecal pole ligation and puncture (CLP) procedures were performed in mice as a standardized model of polymicrobial sepsis. As determined by miRNA-enriched extraction of circulating RNA from serum and quantification by real-time polymerase chain reaction procedure before and at different time points after CLP, induction of sepsis was found to result in alterations of circulating miR-133a, miR-150, miR-155, and miR-193b*, whereas serum levels of miR-29b and miR-125b remained unaffected ( Fig. 1) . By far, the strongest (fold change of 16!) and most significant regulation was observed for circulating miR-133a ( Fig. 1 ). Of note, serum levels of this miRNA became positive to a very early time point after CLP surgery and normalized already 48 hours after surgery in surviving animals, indicating that this distinct miRNA might represent a very sensitive marker for the early identification of sepsis (Supplementary Fig. 1 , Supplemental Digital Content 2, http://links. lww.com/CCM/A806). Of note, this was also the only of the analyzed miRNAs that was up-regulated in all individual animals upon CLP-induced sepsis ( Fig. 1 ).
miR-133a Serum Concentrations Are Elevated in Critically Ill Patients and Sepsis
In order to evaluate a potential function for miR-133a as a marker for critical illness, we measured miR-133a serum concentrations in 223 patients at admission (prior to therapeutic interventions) and 3 days after admission to the ICU (n = 58) and in 76 healthy controls. miR-133a serum concentrations were significantly elevated in critically ill patients ( Fig. 2A) ( Supplementary Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/CCM/A807). Of note, miR-133a serum concentration appeared related to disease severity, as patients with high Acute Physiology and Chronic Health Evaluation (APACHE)-II scores displayed even higher miR-133a serum levels than patients with lower APACHE-II values ( Fig. 2B) . Of note, miR-133a serum concentrations did not correlate with age or sex, neither in controls nor in patients (data not shown). Furthermore, preexisting type 2 diabetes or obesity did not impact serum miR-133a levels in critically ill patients (Supplementary Fig. 3 , Supplemental Digital Content 4, http://links. lww.com/CCM/A808).
Based on our initial hypothesis, we further investigated if the presence of sepsis in critically ill patients might have a specific impact on circulating miR-133a. Remarkably, we found significantly elevated miR-133a serum concentrations at admission to the ICU in patients who fulfilled sepsis criteria, compared with patients with other etiology of critically illness (Fig. 2C) . To investigate the influence of the underlying etiology more precisely, we performed subgroup analysis within the sepsis and nonsepsis patients. When sepsis patients were categorized into pulmonary sepsis, abdominal sepsis, urogenital sepsis, and as septic disease with a different or unknown infectious focus and nonsepsis patients were further subdivided into cardiovascular disorders, liver cirrhosis, and others ( Table 2) , no significant differences between the different groups became apparent ( Fig. 2D) .
Finally, we hypothesized that elevated miR-133a levels could discriminate between sepsis and nonseptic etiology of critical illness. Therefore, we attempted to compare its diagnostic accuracy with other routine laboratory variables for the diagnosis of sepsis. Receiver-operating characteristic (ROC) curve analysis revealed a clear trend toward superior area under the curve (AUC) statistics for miR-133a compared with leukocytes, creatinine, bilirubin, or international normalized ratio but inferior AUC values compared with procalcitonin or CRP ( Supplementary Fig. 4 , Supplemental Digital Content 5, http://links.lww.com/CCM/A809).
Levels of Circulating miR-133a Are Closely Correlated to biomarkers of Inflammation, Organ Function, and Clinical Scores
To elucidate factors potentially affecting serum miR-133a levels, we performed correlation analyses with extensive sets of laboratory variables. Serum miR-133a concentrations were significantly correlated to markers of inflammation and bacterial infection, such as CRP and procalcitonin or TNF and interleukin-10 (Supplementary Table 1 Table 3) .
miR-133a Serum Levels Are a Strong Predictive Marker for ICU and Overall Survival in Critically Ill Patients
Based on the clear correlations between miR-133a, inflammatory markers, organ dysfunction, and prognostic clinical scores, we hypothesized that miR-133a measurements could predict outcome in critically ill patients. We first analyzed whether high miR-133a serum levels are correlated with an unfavorable clinical course according to prolonged ventilation need, an extended treatment time on ICU or a long stay in the clinic. Strikingly patients with miR-133a upper to the median of all patients had significantly higher values in all of these variables ( Supplementary Fig. 5 , Supplemental Digital Content 6, http://links.lww.com/CCM/A810). We, therefore, next compared miR-133a serum concentrations in patients who died during the ICU treatment with those who survived. Interestingly, patients who succumbed to death on ICU displayed significantly higher serum miR-133a concentrations at admission and at day 3 compared with survivors ( Fig. 3A and Supplementary Fig. 7A , Supplemental Digital Content 8, http:// links.lww.com/CCM/A812). Additionally, low miR-133a levels represented a strong prognostic predictor for ICU survival (p = 0.003 at admission, not significant at day 3; Cox regression analysis). Furthermore, patients with miR-133a serum levels within the lowest quartile of all analyzed patients had a significantly better ICU survival than all other patients (Fig. 3B) . Using a cutoff value for serum miR-133a levels of 0.8 relative units, Kaplan-Meier curves revealed a significantly improved ICU survival for critically ill patients with low miR-133a levels at admission to the ICU ( Fig. 3C and Supplementary  Figure 7C , Supplemental Digital Content 8, http://links.lww. com/CCM/A812). Finally, survivors displayed a strong trend toward a stronger decrease in miR-133a concentrations from admission to day 3 (Supplementary Fig. 8 , Supplemental Digital Content 9, http://links.lww.com/CCM/A813). Of note, the extent of this regulation from admission to day 3 was equal to that of CRP levels or the multifactorial Simplified Acute Physiology Score 2 score, thus further highlighting the strength of miR-133a serum levels in estimating the patients' prognosis needing ICU treatment.
When we applied ROC analyses to compare the prognostic value of miR-133a levels for ICU with established prognosis scores in critical illness, miR-133a serum levels achieved similar AUC statistics as the multifactorial APACHE-II score ( Fig. 3D) . Furthermore, miR-133a serum levels displayed higher prognostic accuracy for ICU survival than all solitary biomarkers of inflammation and organ failure, analyzed in this study (Supplementary Fig. 6 , Supplemental Digital Content 7, http://links.lww.com/CCM/A811). In our cohort of critically ill patients, 23.6% died on the ICU while additional 20.3% of patients died after initially successful discharge from ICU. In an analogous manner as for short-term survival, we could reveal that patients who died after release from ICU displayed a strong trend toward higher miR-133a levels at admission than survivors (Fig. 3E) . Similar to ICU survival, Cox regression analyses (p = 0.008) and analyses of Kaplan-Meier survival curves revealed that low miR-133a serum levels predicted favorable long-term fate in critically ill patients (Fig. 3F) . These data indicate that dysregulation of miR-133a might be used not only to identify patients with poor ICU-related mortality but be even relevant for the long-term clinical course of patients after resolving the acute illness. 
Expression of miR-133a Is Up-Regulated in Immune Cells During Septic Disease
It is presently unclear and controversially debated which molecular mechanisms are responsible for alterations in serum miRNA levels in certain disease conditions. Especially, it is not known if changes in serum levels reflect a passive release of miRNAs during cell death or if they are actively secreted and might play a functional role as "messengers." We thus aimed at assessing if the up-regulation of the identified serum miRNAs correlated with their regulation in different organs or cellular compartments that are most likely involved in the pathophysiology of sepsis. For this, we extracted the liver, brain, kidney, spleen, skeletal muscles, heart, and circulating leukocytes from C57BL/6 mice before and after induction of septic disease (Fig. 4) . Strikingly this comprehensive analysis revealed a strong and significant up-regulation of miR-133a specifically in leucocytes, which is in line to the elevated miR-133a serum levels in the serum of mice and human patients with septic disease. On the base of these data, we next performed an in silico target prediction analysis revealing approximately 600 potential target genes for miR-133a. Among these genes, we identified 50 genes with a known relation to inflammatory/septic diseases and a known function in immune cells (Supplementary Table 2 , Supplemental Digital Content 1, http://links. lww.com/CCM/A805). Considering the established role of down-regulated cyclinD1 and insulin receptor in immune cells during sepsis, we attempted to establish a direct link between high miR-133a expression and a down-regulation of insulin receptor (INSR) by transfecting miR-133a into U937 immune cells ( Fig. 4) . Of note, overexpression of miR-133a led to a down-regulation of INSR in these cells, thus suggesting a direct regulation of these genes by miR-133a.
DISCUSSION
Next to their role in regulating gene expression, circulating miR-NAs were recently proposed as serum-based next-generation biomarkers in manifold diseases. The diagnostic potential of serum miRNAs is based on their extraordinary stability and resistance to storage handling. This stability at least partly relies on the inclusion of serum miRNAs in exosomes or microvesicles, where they are protected against degradation or destruction (24, 25) . It was recently demonstrated that the number and serum concentrations of such microvesicles are increased in patients with sepsis (26); thus, similar to the reported changes in microvesicle concentrations, also concentrations of miRNAs might be altered in septic disease. In line with this hypothesis, alterations of serum miRNA concentrations were recently described by different groups in patients with sepsis and critical illness (6) (7) (8) . However, due to the high costs of miRNA array-based approaches, most of these studies applied (array-based) screening technologies on serum samples only from small cohorts or highly selected individual patients. Given the high heterogeneity of critically ill patients at initial presentation to the ICU, it remains unclear whether these data, especially with respect to organ dysfunction or prognosis, can be translated to heterogeneous "real-life" cohorts of patients with critical diseases.
For this study, we hypothesized that such miRNAs that are known to be functionally important in inflammation and infections might represent interesting biomarkers in sepsis and selected a panel of six miRNAs (miR-29b, miR-133a, miR-150, miR-155, miR-193b*, and miR-223), with known functions in inflammatory disease states (9-18) for further analysis. By applying the well-established model of CLP for induction of polymicrobial sepsis in mice, we systematically evaluated whether the functional role of these miRNAs in inflammation could be translated to corresponding changes in serum miRNA concentrations upon experimental sepsis induction. Interestingly, several miRNAs that had been identified by screening approaches from serum samples and already reported to be relevant in sepsis did only show a moderate regulation in the mouse model, for instance, miR-150 or miR-193b* (7, 27) . Of all investigated miRNAs, the miR-133a displayed the most abundant and consistent regulation and was therefore most promising to serve as a biomarker for critical illness and sepsis. To test this hypothesis, we measured miR-133a serum levels of critically ill patients at admission to the ICU and indeed confirmed that compared with healthy volunteers, critically ill patients displayed significantly elevated miR-133a serum concentrations. In accordance to previous findings on systemic inflammation (15) (16) (17) , miR-133a levels were higher in patients who fulfilled sepsis criteria when compared with patients with other etiology of critical illness. Of note, within the group of patients with nonseptic etiology of critical illness, those patients with a cardiopulmonary etiology of critical illness displayed highest miR-133a serum levels, which is in line to previous data, describing elevated levels of miR-133a in the serum of patients suffering from myocardial infarction or muscle injury (13) . Furthermore, patients with liver cirrhosis demonstrated a marked increase in serum miR-133a levels compared with other patients, which is in line to previous findings of our group on cirrhotic patients outside the ICU setting (14) .
We used correlation analysis to identify potential factors driving the up-regulation of miR-133a in patients with critical illness and sepsis. These analyses revealed significant correlations between miR-133a and established laboratory biomarkers reflecting inflammation and infection in medical ICU patients, which is in line to previous data (28, 29) . Furthermore, we detected a striking correlation between elevated miR-133a and liver dysfunction according to impaired liver synthesis capacity and elevated cholestasis variables in patients with high miR-133a levels. Furthermore, critically ill patients with liver cirrhosis displayed higher levels of circulating miR-133a compared with patients without liver cirrhosis, suggesting an influence of liver injury on miR-133a serum levels. In line to these data, we recently demonstrated a stage-dependent elevation in circulating miR-133a levels in patients with chronic liver injury and liver cirrhosis, thus further supporting the liver as a potential source of elevated miR-133a levels in critical illness and sepsis (14) .
However, the pathophysiologic consequences of high circulating miR-133a in critically ill and sepsis patients are not clear at present. We here demonstrate an up-regulation of miR-133a in immune cells during septic disease. This up-regulation was associated to lower levels of cyclinD1 and the insulin receptor in cells overexpressing miR-133a, highlighting a direct link between miR-133a and these sepsis-related genes. Thus, we here provide a novel INSR/cyclinD1-dependent role of miR-133a in sepsis, which is clearly reflected by higher serum concentrations of miR-133a in this setting. Furthermore, by applying in silico target prediction analysis, we identified a panel of direct miR-133a target genes which are directly involved in the pathophysiology of inflammatory and septic diseases specifically in immune cells (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/A805). As such, it was shown that down-regulation of miR-133a induces cell proliferation through direct and indirect targeting of Sp1 and cyclinD1, which are involved in the regulation of cell proliferation and differentiation, representing prognosis determining processes in several diseases (30, 31) . By regulating whole networks of genes or signaling pathways instead of one or few specific genes (as described for most cytokines), miRNA might govern complex pathophysiologic processes such as sepsis or patients survival.
In this study, we demonstrate a prognostic impact of miR-133a serum concentrations at admittance to the ICU in a large cohort of critically ill patients. In particular, patients with high miR-133a serum levels had a significantly impaired prognosis compared with patients with low miR-133a levels.
Our findings that serum miR-133a is a marker of mortality risk provide evidence for a potential role of this miRNA as a novel tool in the initial diagnosis, triaging, and prognostic judgment of critically ill and septic patients. One could further speculate that, besides being used as a single marker, miR-133a may be implemented into established scoring systems to further improve their sensitivity and specificity. However, this assumption is based on a single-center analysis and future prospective studies are needed to test this hypothesis.
The data presented here are especially interesting in light of a recent study comparing genomic profiles in response to different inflammatory stimuli between human patients and corresponding mouse models (31) . This array-based transcriptional profiling study showed hardly any correlation of expression levels of inflammatory genes between humans and mice, thus challenging the translational potential of mouse models in inflammatory disease in general. Of note, our screening approach in a murine model of polymicrobial sepsis and the further analysis in a large cohort of human patients revealed a concordant regulation of miR-133a. Therefore, expression patterns of inflammatory miRNAs might show a higher degree of interspecies conservation than many protein-coding genes, indicating their potential value for translational approaches in diagnosis and therapy of inflammatory disease.
In summary, based on a model of experimental polymicrobial sepsis in mice, our study identifies miR-133a as a new serum marker in critically ill patients to assess disease severity and mortality risk. Low miR-133a serum concentrations were highly predictive for ICU and overall survival. In line miR-133a was significantly associated with inflammation and organ dysfunction, which are central targets in critical disease. Of note, although our data strongly suggest an important pathophysiologic role of miR-133a in critical illness and sepsis, they presently do not provide mechanistic insight on the specific actions of miR-133a in these diseases. Nevertheless, our findings strongly support future functional and clinical analyses on the role of miR-133a in sepsis.
